These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 31707829)
1. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Bhatt DL; Miller M; Brinton EA; Jacobson TA; Steg PG; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Olshansky B; Chung MK; Gibson CM; Giugliano RP; Budoff MJ; Ballantyne CM; Circulation; 2020 Feb; 141(5):367-375. PubMed ID: 31707829 [TBL] [Abstract][Full Text] [Related]
2. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM; J Am Heart Assoc; 2022 Mar; 11(6):e022937. PubMed ID: 35261279 [TBL] [Abstract][Full Text] [Related]
3. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Majithia A; Bhatt DL; Friedman AN; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Budoff M; Preston Mason R; Tardif JC; Boden WE; Ballantyne CM Circulation; 2021 Nov; 144(22):1750-1759. PubMed ID: 34706555 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM; N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628 [TBL] [Abstract][Full Text] [Related]
5. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Verma S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Dhingra NK; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Mason RP; Tardif JC; Ballantyne CM; Circulation; 2021 Dec; 144(23):1845-1855. PubMed ID: 34710343 [TBL] [Abstract][Full Text] [Related]
12. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Gaba P; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Giugliano RP; Martens FMAC; Gibson CM; Ballantyne CM; J Am Coll Cardiol; 2022 May; 79(17):1660-1671. PubMed ID: 35483753 [TBL] [Abstract][Full Text] [Related]
13. Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice? Ferrières J; Bataille V; Puymirat E; Schiele F; Simon T; Danchin N; Clin Cardiol; 2020 Nov; 43(11):1260-1265. PubMed ID: 32720384 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. Gencer B; Mach F; Murphy SA; De Ferrari GM; Huber K; Lewis BS; Ferreira J; Kurtz CE; Wang H; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP JAMA Cardiol; 2020 Aug; 5(8):952-957. PubMed ID: 32432684 [TBL] [Abstract][Full Text] [Related]
15. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147 [TBL] [Abstract][Full Text] [Related]
16. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Trivedi K; Le V; Nelson JR Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268 [TBL] [Abstract][Full Text] [Related]
17. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Chapman MJ; Zamorano JL; Parhofer KG Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222 [TBL] [Abstract][Full Text] [Related]
18. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E; Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150 [TBL] [Abstract][Full Text] [Related]
19. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. Deedwania P; Murphy SA; Scheen A; Badariene J; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR; Sabatine MS; Giugliano RP JAMA Cardiol; 2021 Feb; 6(2):139-147. PubMed ID: 32785614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]